CG Oncology CGON EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from CG Oncology’s reported figures.
Based on trailing twelve months.
The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about CG Oncology's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CG Oncology's EBITDA margin?
- CG Oncology (CGON) reported EBITDA margin of -4,194.4% in Q1 2026.
- How has CG Oncology's EBITDA margin changed year-over-year?
- CG Oncology's EBITDA margin increased by 79.3% year-over-year, from -20,294.4% to -4,194.4%.
- What is the long-term trend for CG Oncology's EBITDA margin?
- Over 2 years (2023 to 2025), CG Oncology's EBITDA margin has grown at a -58.5% compound annual growth rate (CAGR), from -27,170.6% to -4,686.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.